Nachrichten zur Abbvie Inc. Aktie

AbbVie-Aktie: Deshalb gefällt diese Mega-Übernahme

Nach der Ankündigung einer 10 Milliarden US$ schweren Übernahme hat die Aktie von AbbVie (WKN: A1J84E) am Donnerstag um +3,5%…

Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More

AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by…

AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors…

AbbVies $10bn Deal For ImmunoGen: Fundamentals And Rationale Explained

…

Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion

Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the…

Biotech-Milliardendeal: US-Pharmariese AbbVie schluckt ImmunoGen - Aktie verdoppelt sich nahezu!

AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio

…

HBM Healthcare Investments AG: AbbVie erwirbt HBM-Portfoliounternehmen ImmunoGen für USD 10.1 Milliarden in bar

HBM Healthcare Investments AG / Schlagwort(e): Fusionen & Übernahmen AbbVie erwirbt HBM-Portfoliounternehmen ImmunoGen für USD 10.1 Milliarden in bar 30.11.2023…

EQS-News: AbbVie erwirbt HBM-Portfoliounternehmen ImmunoGen für USD 10.1 Milliarden in bar (deutsch)

AbbVie erwirbt HBM-Portfoliounternehmen ImmunoGen für USD 10.1 Milliarden in bar ^ HBM Healthcare Investments AG / Schlagwort(e): Fusionen &…

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

IMGN stock soared after AbbVie agreed to buy ImmunoGen for $10.1 billion, offering a rich premium for the maker of…

Immunogen shares surge on news of takeover by AbbVie By Investing.com

Immunogen shares surge on news of takeover by AbbVie…

ImmunoGen Stock Soars 80% on AbbVie’s $10.1 Billion Takeover

…

Pharmaceutical company AbbVie buying ImmunoGen in $10.1 billion deal

…

ImmunoGen: AbbVie greift zu! Aktienanalyse

Kulmbach (www.aktiencheck.de) - ImmunoGen-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die ImmunoGen-Aktie (ISIN:…

AbbVie to acquire cancer drugmaker ImmunoGen for $10B cash (update)

…

AbbVie to Buy ImmunoGen for More Than $10 Billion

…

AbbVie signs $10 billion deal to buy cancer drugmaker ImmunoGen

…

AbbVie schluckt AKTIONÄR-Hot-Stock Immunogen – Aktie schießt über 80 Prozent hoch

Der Pharma-Riese AbbVie will sein Onkologie-Business mit der Übernahme von Immunogen ausbauen und legt dafür satte 10,1 Milliarden Dollar auf…

AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio By Reuters

AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio…

: AbbVie $10.1 billion deal to buy ImmunoGen values the stock at a 95% premium

AbbVie Inc. ABBV announced Thursday an agreement to buy cancer treatment developer ImmunoGen Inc. IMGN in a cash deal valued…

Biotech Stocks Rally After $10.1 Billion ImmunoGen Buyout

Big pharma’s $10.1 billion deal splash is giving biotech stocks a lift. AbbVie, which sells widely-used drugs like Humira and Skyrizi,…

AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade)

…

AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study

Data from a mid-stage study on AbbVies (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain…

[Latest] Global Organ Transplantation Market Size/Share Worth USD 21.5 Billion by 2032 at a 9.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024

…

Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031

Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…

4 Large Drug Stocks to Watch as IBD Market Gains Traction

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players…

AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag

The FDA grants breakthrough therapy designation to AbbVies (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing…

: AbbVie says FDA has granted breakthrough therapy designation to epocritamab for a type of lymphoma

AbbVie Inc. ABBV said Monday the U.S. Food and Drug Administration has granted breakthrough therapy designation, or BTD, to its…

Rising Global Prevalence of Skin Diseases Drives the Antipruritics Market, Future Market Insights Predicts Expansion at a 4.2% CAGR through 2034

The growing geriatric population, rising burden of skin diseases, and rising R&D on novel biopharmaceuticals. AbbVie Inc., Allergan, Merck &…

Global Glaucoma Treatment Market Size To Grow USD 10.5 Billion by 2032 | CAGR of 5.0%

The Global Glaucoma Treatment Market Size was valued at USD 6.4 Billion in 2022 and the Worldwide Glaucoma Treatment Market…

AbbVie suing Sandoz, four others to block generic Rinvoq: report

…

Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study

Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…

AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks

…

AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?

Both companies share prices have slipped recently.…

AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell? @themotleyfool #stocks $ABBV $PFE